Zacks Research Brokers Lower Earnings Estimates for Chemours

The Chemours Company (NYSE:CC) – Zacks Research cut their FY2026 earnings per share estimates for Chemours in a report issued on Tuesday, August 18th. Zacks Research analyst Team now forecasts that the specialty chemicals company will post earnings of $0.83 per share for the year, down from their prior forecast of $0.90. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $0.88 per share. Zacks Research also issued estimates for Chemours’ Q4 2026 earnings at $0.11 EPS, Q4 2027 earnings at $0.61 EPS, FY2027 earnings at $2.05 EPS, Q1 2028 earnings at $0.56 EPS and Q2 2028 earnings at $0.65 EPS.

Other equities analysts also recently issued research reports about the stock. The Goldman Sachs Group reiterated a “neutral” rating and issued a $17.00 price target on shares of Chemours in a report on Thursday, August 13th. JPMorgan Chase & Co. decreased their price objective on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating on the stock in a report on Thursday, August 13th. Morgan Stanley set a $18.00 target price on shares of Chemours in a research report on Monday, August 10th. Royal Bank Of Canada dropped their target price on shares of Chemours from $26.00 to $22.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Finally, BMO Capital Markets reduced their price target on shares of Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a research report on Thursday, August 13th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Chemours currently has an average rating of “Hold” and a consensus target price of $20.10.

Chemours Price Performance

Shares of NYSE CC opened at $15.89 on Thursday. The firm has a market capitalization of $2.39 billion, a P/E ratio of -8.32 and a beta of 1.43. Chemours has a one year low of $10.44 and a one year high of $28.67. The company’s fifty day moving average is $18.25 and its two-hundred day moving average is $20.04. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.88 and a current ratio of 1.66.

Chemours (NYSE:CC) last released its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%.The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter in the previous year, the company posted ($2.54) EPS. The company’s revenue was down 1.5% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Atlas Capital Advisors Inc. acquired a new stake in Chemours during the 4th quarter valued at $26,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Chemours in the fourth quarter valued at $28,000. Covestor Ltd boosted its stake in shares of Chemours by 204.7% during the fourth quarter. Covestor Ltd now owns 2,602 shares of the specialty chemicals company’s stock valued at $31,000 after acquiring an additional 1,748 shares during the last quarter. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Chemours during the fourth quarter valued at $31,000. Finally, Rothschild Investment LLC increased its position in Chemours by 87.0% during the 4th quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company’s stock worth $32,000 after purchasing an additional 1,255 shares in the last quarter. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Chemours

In other Chemours news, CFO Shane Hostetter bought 3,350 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was purchased at an average cost of $14.94 per share, for a total transaction of $50,049.00. Following the acquisition, the chief financial officer owned 102,698 shares of the company’s stock, valued at $1,534,308.12. The trade was a 3.37% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Calderon Gerardo Familiar bought 1,935 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were acquired at an average price of $15.53 per share, with a total value of $30,050.55. Following the transaction, the insider owned 58,547 shares of the company’s stock, valued at $909,234.91. The trade was a 3.42% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders acquired 8,663 shares of company stock worth $130,601. 0.85% of the stock is owned by corporate insiders.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 14th will be paid a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Friday, August 14th. Chemours’s dividend payout ratio is presently -18.32%.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.